- •CONTENTS
- •Contributors
- •Preface
- •I Components of Angiogenic Cascades
- •1. Introduction and Historical Perspective
- •2. The Semaphorins
- •3. The Plexin Receptor Family
- •4. The Neuropilins
- •5. Vascular Endothelial Growth Factors and Their Receptors
- •6. Signal Transduction by Neuropilins
- •7. The Role of the Neuropilins in the Regulation of Vasculogenesis and Angiogenesis
- •8. Modulation of Angiogenesis by Semaphorins that Bind Directly to Plexins
- •Acknowledgments
- •References
- •1. Introduction
- •1.1. Eph receptor domain structure
- •1.2. The ephrin domain structure
- •2. Effects on Vascular Cell Behavior and Signaling Pathways
- •2.1. Ephrin-A1 and EphA2
- •2.2. Ephrin-A1 and EphA4
- •2.3. Ephrin-B and EphB
- •2.3.1. EphB forward signaling
- •2.3.2. Ephrin-B reverse signaling
- •2.4. Crosstalk with other angiogenic pathways
- •3. Endothelial Cell Fate
- •4. Angiogenic Remodeling of Embryonic Blood Vessels
- •4.1. Ephrin-A1 and EphA receptors
- •4.2. EphB4 and Ephrin-B2
- •4.3. Other EphB receptors and Ephrin-Bs
- •5. Lymphatic Vessels
- •6. Adult Vasculature
- •6.1. Quiescent vasculature
- •6.2. Physiological angiogenesis
- •6.3. Inflammation and wound healing
- •6.4. Tumor angiogenesis
- •6.4.1. Ephrin-A1 and EphA2
- •6.4.2. Ephrin-B2 and EphB4
- •8. Perspectives
- •Acknowledgments
- •References
- •1. Introduction
- •2. Molecular Mechanisms
- •3. Role in Vascular Development
- •4. FGFs in Tumor Angiogenesis
- •5. Role of FGFs in Developmental and Tumor Lymphangiogenesis
- •7. Conclusion
- •Acknowledgments
- •References
- •1. The NPY System
- •2. NPY as a Growth Factor for Vascular Cells
- •3. DPPIV: A Molecular Switch of the NPY Angiogenic System
- •4. Downstream Mediators of NPY Actions
- •5. NPY in Revascularization of Ischemic Tissues
- •6. NPY in Wound Healing
- •7. NPY in Adipose Tissue Growth and Obesity
- •8. NPY in Retinopathy
- •10. NPY in Tumor Angiogenesis
- •11. NPY-Mediated Angiogenesis and Neurogenesis
- •References
- •1. Introduction
- •2. Historical Perspective
- •3.1. The HSPG core proteins
- •3.2. The structure of the HS chain
- •3.3. The biosynthesis of HS
- •3.4. The post-synthetic processing of HSPGs
- •4. Evolution of HSPGs
- •5. HSPGs in Development
- •6. HSPG Modulation of Ligand-Receptor Interactions
- •6.2. HSPG co-receptors confer unique regulatory properties
- •6.2.1. Co-receptors engender stoichiometric control of signaling
- •6.2.2. The effects of glycanation
- •6.2.3. HS sequence motifs regulate signaling
- •7. HSPGs Enable Global Control of EC Phenotype
- •8. Future Therapeutic Directions
- •9. Conclusions
- •References
- •II Angiogenic Regulators
- •1. Introduction: Blood Vessels and Nerves Use Similar Guidance Cues
- •2. Semaphorin Signaling
- •2.1. Neuropilins
- •2.2. Plexins
- •3. Ephrins and Eph Signaling
- •3.1. Forward signaling
- •3.2. Reverse signaling
- •4. Netrin and Slit Signaling
- •5. Open Questions
- •References
- •1. Oxygen Homeostasis: Phylogeny, Ontogeny, Physiology, and Pathobiology
- •5. Control of Angiogenesis and Arteriogenesis by HIF-1
- •6. Control of Tumor Angiogenesis by HIF-1
- •References
- •1. Introduction
- •2. Reactive Oxygen Species (ROS) in the Vasculature
- •3. ROS and Angiogenesis
- •4. NAD(P)H Oxidase: A Major Source of ROS in the Vasculature
- •5. Role of NAD(P)H Oxidase in Angiogenesis
- •6. ROS as Signaling Molecules in Angiogenesis
- •8. Conclusion
- •References
- •1. Introduction
- •2. Assessing Coronary Angiogenesis and Arteriogenesis
- •3. Pressure Overload-Induced Hypertrophy
- •4. Volume Overload-Induced Cardiac Hypertrophy
- •5. Thyroxine-Induced Hypertrophy
- •6. Hypoxia-Induced Hypertrophy
- •7. Exercise-Induced Hypertrophy
- •8. Myocardial Infarction-Induced Hypertrophy
- •9. Modulators of Angiogenesis During Hypertrophy
- •10. Stimuli of Angiogenesis During Hypertrophy
- •11. Summary
- •References
- •1. Introduction
- •2. Coronary Resistance
- •3. Regulation of Coronary Microvascular Tone
- •3.1. Intrinsic and extrinsic vasomotor control
- •3.2. Role of the endothelium
- •3.3. Role of metabolism and autoregulation
- •3.4. Flow-induced dilation
- •3.5. Neurohumoral influence on microcirculation
- •3.6. Intrinsic myogenic tone
- •3.7. Impact of extravascular and humoral factors on the coronary microcirculation
- •3.8. Role of venules in coronary resistance
- •4. Endothelial Factors in Vascular Growth and Response to Injury
- •5. Impact of Disease States on Coronary Circulation
- •6. The Coronary Microcirculation in Hypertophic States
- •7. Summary
- •References
- •III Clinical Applications
- •1. Kinase Inhibition and Tumor Angiogenesis
- •2. Major Angiogenesis Factors and Receptors
- •2.1. VEGF signaling
- •3. Further Angiogenesis-Related Signaling
- •4. Need for Selectivity of Anti-Angiogenic Kinase Inhibitors
- •5. Kinase Inhibitors in Clinical Development
- •5.1. BAY 43-9006 (Sorafenib)
- •5.2. PTK/ZK (Vatalanib)
- •5.3. SU11248 (Sunitinib)
- •5.9. BIBF 1120
- •5.10. Chir-258
- •5.12. SU5416 (Semaxinib)
- •6. Challenges and Future Directions
- •Acknowledgments
- •References
- •1. Introduction
- •2. Concepts and Rationales
- •3. Strategy
- •4. Clinical Trials
- •4.1. Growth factor-based, angiogenic approach
- •4.2. Cell therapy-based, vasculogenic and paracrine approach
- •5. Issues Regarding Current Strategy
- •5.1. Choice of biological agent
- •5.2. Pharmacokinetics and delivery mode
- •5.3. Monitoring of neovascularization
- •5.4. Study design
- •6. Emerging Concepts of Therapeutic Angiogenesis
- •6.1. Neovascularization responsiveness
- •6.2. Genetic determination of neovascularization
- •7. Future Prospective
- •8. Summary
- •References
- •1. Hepatocyte Growth Factor in Cardiovascular System
- •2. HGF Signaling in Endothelial Cells
- •3. Angiogenic Therapy for Ischemic Peripheral Arterial Diseases
- •4. Clinical Trial in PAD
- •5. HGF Gene Therapy for Myocardial Ischemia
- •6. HGF Gene Therapy for Restenosis After Angioplasty
- •7. Next Five Years Perspective — Future Direction of HGF Therapy
- •Acknowledgments
- •References
- •1. Endothelial Nitric Oxide in Health and Disease
- •1.1. Nitric oxide synthases
- •1.2. Physiological role of endothelial NO (“EDNO”)
- •1.3. Endothelial NO-deficiency in cardiovascular diseases
- •1.4. Therapeutic restoration of endothelial NO production in cardiovascular diseases
- •2. Nitric Oxide and Angiogenesis
- •2.2. Tumor angiogenesis and NO
- •2.3. Evidence in cultured endothelial cells and in rabbit cornea
- •2.4. Role of NO in post-ischemic revascularization
- •2.6. Molecular mechanisms
- •3. NOS Gene Transfer
- •3.1. Gene delivery vectors
- •3.2. NOS-III gene transfer
- •3.3. NOS-II gene transfer
- •4.1. Impaired angiogenesis and arteriogenesis in patients with critical limb ischemia
- •4.2.1. NOS-III-KO mice
- •4.2.2. NOS-III transgenic mice
- •4.2.3. Wild-type NOS-III gene transfer in normal rats
- •4.5.1. Plasmid delivery of the NOS1177D gene
- •4.5.2. Adenoviral delivery of the NOS1179D gene
- •6. Conclusions
- •Acknowledgments
- •References
- •Index
Modulation of Growth Factor Signaling by Heparan Sulfate Proteoglycans |
129 |
from leukocytes, tumor cells or the endothelium can degrade HS chains.38 Second, nitric oxide can damage HS chains. Such HSPGs are repaired by undergoing cellular internalization, damaged chain regions are removed, fresh HS chains are re-synthesized on the core proteins, and the repaired HSPG is transported back to the cell surface.39 Third, extracellular sulfatases, which remove specific sulfate moieties, can modify HS motifs. For example, 6-O-sulfate groups can be removed by the Sulf enzymes.40 Fourth, proteoglycans bound to the cell membrane can be shed. Phospholipase activity liberates GPI-linked HSPGs whereas shedding of integral membrane HSPGs involves protease cleavage of the extracellular domain near the transmembrane domain.11 Thus, the HSPG structure can be altered by multiple extracellular factors. The potential influence of such factors on HS-mediated cell signaling is discussed below.
4. Evolution of HSPGs
An evolutionary perspective reveals many fundamental features of HSPGs. Bona fide HS polysaccharide has not been found in plants, unicellular organisms, or prokaryotes. Rigorous structural studies have found that HS occurs in most metazoans, being absent only from the most primitive multicellular animal, the sponges. The two more complex phyla Ctenophora and Cnidaria, whose ancestors represent the earliest forms of Eumetazoa (true metazoans), clearly possess vertebrate-type HS structures (reviewed in Refs. 41 and 42). The long split between Eumetazoans and sponges, 940 million years ago, testifies to the extreme antiquity of HS. On one hand, HS may have arisen by conferring a selection advantage through optimizing pre-existent processes. Potential candidates include processes which were firmly established in single cell organisms, such as cell signaling and adhesion. Additional candidates include totipotent stem cells, innate immunity, chemokine production, and apoptosis, which all occur in sponges. On the other hand, the emergence of the complex HS biosynthetic pathway may have involved selection for a unique process appearing at the divergence of Eumetazoans. In particular, the emergence of an integrated mechanism for whole organ homeostasis enabled this evolutionary
130 N. W. Shworak
split.43 Eumetazoa does not include the sponges because they essentially function like a colony of animals. Sponges are comprised of a semiautonomous groups of cells. Each group has an independent inlet to obtain seawater that contains food/oxygen and an independent outlet for removal of waste/carbon dioxide. The earliest Eumetazoans, in contrast, have a single inlet into and a single outlet draining a common gastrovascular cavity. This specialized sealed compartment is surrounded by an evolutionarily novel sheet of cells, the original “epithelium sensu stricto.” This cell layer serves to regulate and separate the fluids in distinct extracellular compartments. Thus, Eumetazoans are characterized by a single circulatory system that enables whole body homeostasis.43
An increase in cellular diversity accompanied this change in body plan. Whereas sponges arise from a single germ layer, early Eumetazoans had two germ layers (endoderm and ectoderm) that enabled the formation of the new epithelium sensu stricto. Neurons were an additional novel early Eumetazoan cell type, which allowed for further coordination of whole body homeostasis. Thus, the emergence of Eumetazoans featured the simultaneous development of primitive circulatory and nervous systems. This common emergence might explain why both systems in higher organisms frequently employ similar signaling components such as FGFs, neuropilins, ephrins and Notch receptors, as elaborated below. From such primordial evolutionary roots, it is not surprising that HSPGs are involved in homeostatic mechanisms, serve to modulate cell type-specific phenotypes, occur in multiple organ systems and regulate embryonic development.
The advent of total genome sequencing has revealed the extent of the lower metazoan HS biosynthetic machinery as known for the roundworm (C. elegans) and the fruit fly (Drosophila melanogaster). These organisms possess genes encoding multiple core proteins and all of the various HS biosynthetic enzymes; thus all the components for HSPG production are present. Numerous studies show that the mammalian and invertebrate gene products are functionally equivalent (reviewed in Ref. 12). However, these invertebrates, in contrast to vertebrates, largely lack multigene families. They exhibit only single genes for NDST, HS6ST, syndecan, and glypican. A notable exception is that Drosophila shows two HS3ST genes which respectively encode gD-type
Modulation of Growth Factor Signaling by Heparan Sulfate Proteoglycans |
131 |
and AT-type isoforms.35 Thus, these two isoforms stem from the same predecessors of the two major functional groupings of the large mammalian 3-O-sulfortransferase multigene family.
5. HSPGs in Development
The roles of HS in development have been most extensively examined in C. elegans and Drosophila. These invertebrates are not useful for directly studying vascular development as they only have a rudimentary open circulatory system. Nevertheless, fundamental features of the roles of HS in development are revealed by the genetic investigations of these animals. Most importantly, these studies demonstrate a role for HSPGs in several signaling pathways that are known to be operable in vertebrate ECs. Thus, genetic analyses of such lower organisms exemplify potential ways in which HSPGs may function in mammalian ECs.
Studies of mutants lacking various core proteins show that each core is required for signaling events that are specific in time, place, cell type and tissue, and that HSPGs are required for the development of multiple organ systems (reviewed in Refs. 12 and 44). That each protein conveys discrete functions suggests the multitude of core proteins expressed in mammalian ECs should serve to expand endothelial functional diversity. Deletion of a single core protein in lower organisms is not usually lethal, due to the multiplicity of core proteins. However, early embryonic death occurs in Drosophila and C. elegans mutants that have core proteins but are completely lacking in HS (due to mutations in EXT enzymes, see Fig. 2, that prevent polymerization of the HS backbone). Such lethality shows that the HS component of HSPGs plays an essential role in development. The HS-deficient Drosophila mutants show defects in pathways mediated by three HS-binding signaling ligands (wingless, hedgehog, and decapentaplegic, which is a form of tumor growth factor-β (reviewed in Refs. 12 and 44). It is likely that mammalian ECs employ HS to regulate these pathways, as vertebrates have comparable ligands that are known to be involved in vasculogenesis and angiogenesis.
Genetic studies also show distinct roles for HS modification enzymes. Although global HS deficiency is lethal in C. elegans, mutants lacking
132 N. W. Shworak
either C5-epimerase, HS2ST or HS6ST are viable. All such mutants have abnormal neuronal guidance; however, each enzyme deficiency affects a unique assortment of specific neurons. Thus, unique properties to HS are conveyed by different HS modifications in a cell type-specific fashion. These deficiencies interfere with developmental processes involving three receptors (Robo, Integrin and Ephrin) (reviewed in Refs. 12 and 44). Signaling through the vertebrates forms of all of these receptors is known to involve HSPGs, with integrins and ephrin receptors controlling key endothelial functions.
In Drosophila, deficiencies of specific HS modification enzymes leads to malformation of key organ systems and lethality. Drosophila mutants lacking a gD-type HS3ST isoform have disrupted signaling through the Notch receptor, which produces multiple developmental defects. The vertebrate Notch pathway conveys an arterial cell phenotype to non-committed ECs;45 thus, a mammalian gD-type HS3ST isoform may participate in this form of EC differentiation. Drosophila mutants lacking HS6ST die from malformation of the tracheal airway system.35,46 Development of the Drosophila trachea is analogous to vertebrate angiogenesis. Both processes control branching morphogenesis of tubular structures through comparable signaling components (including FGFs). The Drosophila HS6ST and FGF receptor (breathless) are co-expressed in tracheal cells; whereas, adjacent inducing cells express branchless (the Drosophila FGF). Mutants lacking branchless or breathless or HS6ST activity have stunted branching of the tracheal system that is phenotypically equivalent. Moreover, FGF-dependent activation of mitogen-activated protein kinase is impaired in HS6STdeficient mutants.46 Thus, 6-O-sulfates of HS are essential for FGFinduced branching morphogenesis in Drosophila. Mammalian FGF signaling also requires these moieties, as elaborated below. Clearly, such genetic investigations into the developmental roles of HS in lower organisms should facilitate the identification and delineation of HS-mediated signaling mechanisms that are operable in vertebrate ECs.
Roles of HS in vertebrate vessel development are now beginning to come to light. HS is critical for the signaling activity of VEGF164 and VEGF188, the splice variants of VEGF-A that contain HS-binding domains. Mice that exclusively express VEGF120 (non-HS-binding)
